TABLE 3.
Hazard ratios (HRs) and 95% confidence intervals (CIs) of cancer risk in relationship to serum albumin by gender, body mass index (BMI), and smoking status, Kailuan cohort
Serum albumin (g/L) | Gender | BMI | Smoking status | ||||
---|---|---|---|---|---|---|---|
Male | Female | Normal weight (BMI < 25 kg/m2) | Overweight (BMI ≥ 25 kg/m2) | Non‐smoker | Ever smoker | ||
All cancers | |||||||
Quartile 1 | <44.6 | Ref | Ref | Ref | Ref | Ref | Ref |
Quartile 2 | 44.6–45.9 | 0.86 (0.72–1.03) | 1.08 (0.81–1.44) | 0.89 (0.72–1.11) | 0.94 (0.76–1.17) | 0.93 (0.77–1.12) | 0.89 (0.69–1.16) |
Quartile 3 | 46.0–47.9 | 0.82 (0.70–0.97) | 0.80 (0.61–1.06) | 0.83 (0.68–1.01) | 0.78 (0.64–0.96) | 0.77 (0.65–0.92) | 0.86 (0.69–1.08) |
Quartile 4 | ≥48.0 | 0.73 (0.61–0.87) | 0.85 (0.61 −1.18) | 0.74 (0.59–0.92) | 0.73 (0.58–0.91) | 0.75 (0.61–0.91) | 0.73 (0.56–0.93) |
Lung cancer | |||||||
Quartile 1 | <44.6 | Ref | Ref | Ref | Ref | Ref | Ref |
Quartile 2 | 44.6–45.9 | 0.76 (0.54–1.07) | 1.18 (0.56–2.48) | 0.72 (0.47–1.09) | 0.97 (0.62–1.52) | 0.82 (0.55–1.24) | 0.81 (0.51–1.29) |
Quartile 3 | 46.0–47.9 | 0.70 (0.52–0.95) | 0.52 (0.22–1.24) | 0.63 (0.43–0.93) | 0.75 (0.49–1.14) | 0.51 (0.34–0.77) | 0.89 (0.60–1.32) |
Quartile 4 | ≥48.0 | 0.69 (0.50–0.96) | 0.85 (0.34–2.11) | 0.60 (0.39–0.92) | 0.84 (0.54–1.31) | 0.71 (0.47–1.08) | 0.71 (0.45–1.12) |
Colorectal cancer | |||||||
Quartile 1 | <44.6 | Ref | Ref | Ref | Ref | Ref | Ref |
Quartile 2 | 44.6–45.9 | 0.74 (0.45–1.21) | 1.61 (0.62–4.18) | 1.16 (0.62–2.18) | 0.67 (0.37–1.23) | 0.78 (0.45–1.33) | 1.07 (0.52–2.21) |
Quartile 3 | 46.0–47.9 | 0.86 (0.57–1.31) | 1.36 (0.55–3.35) | 1.28 (0.73–2.23) | 0.73 (0.44–1.22) | 0.94 (0.59–1.48) | 0.97 (0.50–1.86) |
Quartile 4 | ≥48.0 | 0.40 (0.23–0.69) | 0.61 (0.16–2.32) | 0.78 (0.39–1.53) | 0.22 (0.10–0.51) | 0.39 (0.20–0.76) | 0.53 (0.23–1.21) |
Breast cancer a | |||||||
Quartile 1 | <44.6 | N.A. | Ref | Ref | Ref | Ref | N.A. |
Quartile 2 | 44.6–45.9 | N.A. | 1.37 (0.84–2.25) | 2.04 (0.88–4.71) | 1.14 (0.60–2.15) | 1.42 (0.86–2.33) | N.A. |
Quartile 3 | 46.0–47.9 | N.A. | 0.80 (0.48–1.34) | 1.34 (0.58–3.07) | 0.57 (0.28–1.16) | 0.83 (0.49–1.39) | N.A. |
Quartile 4 | ≥48.0 | N.A. | 1.34 (0.80–2.25) | 1.91 (0.81–4.52) | 1.13 (0.57–2.22) | 1.39 (0.82–2.34) | N.A. |
Liver cancer | |||||||
Quartile 1 | <44.6 | Ref | Ref | Ref | Ref | Ref | Ref |
Quartile 2 | 44.6–45.9 | 0.47 (0.26–0.87) | 1.71 (0.34–8.60) | 0.45 (0.18–1.11) | 0.63 (0.31–1.27) | 0.64 (0.33–1.27) | 0.40 (0.15–1.06) |
Quartile 3 | 46.0–47.9 | 0.44 (0.26–0.75) | 0.34 (0.04–3.25) | 0.44 (0.20–0.97) | 0.45 (0.23–0.87) | 0.36 (0.18–0.75) | 0.55 (0.27–1.13) |
Quartile 4 | ≥48.0 | 0.58 (0.35–0.95) | 0.73 (0.07–7.15) | 0.53 (0.24–1.15) | 0.63 (0.33–1.17) | 0.52 (0.26–1.02) | 0.68 (0.34–1.37) |
Gastric cancer b | |||||||
Quartile 1 | <44.6 | Ref | N.A. | Ref | Ref | Ref | Ref |
Quartile 2 | 44.6–45.9 | 1.20 (0.66–2.18) | N.A. | 1.06 (0.50–2.23) | 1.04 (0.47–2.30) | 1.22 (0.62–2.40) | 0.80 (0.32–2.01) |
Quartile 3 | 46.0–47.9 | 0.91 (0.52–1.62) | N.A. | 0.85 (0.42–1.71) | 0.65 (0.29–1.44) | 0.62 (0.30–1.29) | 0.94 (0.44–2.02) |
Quartile 4 | ≥48.0 | 0.78 (0.42–1.47) | N.A. | 0.57 (0.24–1.34) | 0.67 (0.29–1.58) | 0.76 (0.35–1.63) | 0.47 (0.18–1.24) |
Adjusted for age (10‐year interval), gender, education level (illiterate or primary school, junior high school, senior high school, and college and above), income status (<500 yuan per month, 500–1000 yuan per month, ≥1000 yuan per month), coal dust exposure status (non‐exposure, exposure), BMI (BMI <18.5, 18.5 ≤ BMI <25.0, 25.0 ≤ BMI <30.0, BMI ≥30.0), C‐reactive protein (<0.5, 0.5–1.0, 1.1–2.5, >2.5, mg/L), frequency of smoking (non‐smoker, ex‐smoker, <1 cigarette per day, ≥1 cigarette per day), frequency of alcohol drinking (never drinker, ever drinker), HBsAg infection status (negative and positive). Grouping variables were excluded for each subgroup.
Only females were included for analysis of breast cancer. For female ever smokers, the analysis was infeasible due to the limitation of subjects’ number.
The analysis of gastric cancer risk among female was infeasible due to the limitation of cancer cases.